Molecular Imaging of Cardiac Amyloidosis
- PMID: 32482792
- PMCID: PMC9374028
- DOI: 10.2967/jnumed.120.245381
Molecular Imaging of Cardiac Amyloidosis
Abstract
Transthyretin and light-chain amyloidosis are the 2 main causes of cardiac amyloidosis. Recent developments in molecular imaging have transformed our ability to diagnose transthyretin cardiac amyloidosis noninvasively and unmasked a hitherto unrecognized prevalence of the disease. This review summarizes the current and evolving imaging approaches, their molecular structural basis, and the gaps in imaging capabilities that have arisen as a result of parallel developments in pharmacotherapy delivering the first effective treatment options for this condition.
Keywords: ATTR; SPECT; bone-seeking tracers; cardiac amyloidosis; molecular imaging.
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.
Figures
References
-
- Orphan drug regulations: regulatory history. U.S. Food and Drug Administration website. http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditio.... Revised February 28, 2018. Accessed June 5, 2020.
-
- Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol. 2015;24:343–350. - PubMed
-
- Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349:583–596. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials